Obinutuzumab
- Generic Name
- Obinutuzumab
- Brand Names
- Gazyva, Gazyvaro
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 949142-50-1
- Unique Ingredient Identifier
- O43472U9X8
- Background
Obinutuzumab is a humanized monoclonal antibody used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia. It was approved by the FDA in November 2013 and is marketed under the brand name Gazyva. There is a black box warning of fatal Hepatitis B Virus (HBV) reactivation and fatal Progressive Multifocal Le...
- Indication
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
- Associated Conditions
- Refractory Follicular Lymphoma, Previously untreated Chronic lymphocytic leukemia
- Associated Therapies
- -
A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- Conditions
- Interventions
- First Posted Date
- 2014-10-15
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Pharmacyclics LLC.
- Target Recruit Count
- 229
- Registration Number
- NCT02264574
- Locations
- 🇬🇧
Site Reference ID/Investigator# 0867, Harlow, Essex, United Kingdom
🇦🇺Site Reference ID/Investigator# 0888, Ballarat, Victoria, Australia
🇦🇹Site Reference ID/Investigator# 0869, Salzburg, Austria
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-10-06
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 331
- Registration Number
- NCT02257567
- Locations
- 🇳🇱
UMC St. Radboud; Hematology, Nijmegen, Netherlands
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Swedish Cancer Inst., Seattle, Washington, United States
Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 445
- Registration Number
- NCT02242942
- Locations
- 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇮🇹Az. Osp. S. Maria; Dept. Di Oncologia Medica, Terni, Umbria, Italy
🇦🇹Wilhelminenspital; I. Medizinische Abt., Wien, Austria
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT02220842
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Sloan Kettering Cancer Center, New York, New York, United States
🇫🇷Hôpital Saint-Louis, Paris, France
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 158
- Registration Number
- NCT02174172
- Locations
- 🇺🇸
HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Participants With Refractory or Relapsed Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2014-02-25
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 72
- Registration Number
- NCT02071225
- Locations
- 🇪🇸
Hospital General Universitario de Elche; Servicio de Hematologia, Elche, Alicante, Spain
🇪🇸Hospital de Cabueñes; Servicio de Hematología y Hemoterapia, Gijon, Asturias, Spain
🇪🇸Hospital De Txagorritxu; Servicio de Hematologia, Vitoria, Alava, Spain
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL
- Conditions
- Interventions
- First Posted Date
- 2014-02-05
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 267
- Registration Number
- NCT02055820
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇦🇺Royal Melbourne Hospital, Parkville, Victoria, Australia
🇦🇹Medizinische Universität Wien, Wien, Austria
CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2)
- Conditions
- Interventions
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 787
- Registration Number
- NCT02053610
CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)
- Conditions
- Interventions
- First Posted Date
- 2013-12-02
- Last Posted Date
- 2018-09-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 787
- Registration Number
- NCT01998880
A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2023-03-14
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 85
- Registration Number
- NCT01992653
- Locations
- 🇫🇷
Hopital Henri Mondor, Unite Hemopathies lymphoides, Creteil, France
🇺🇸Banner MD Anderson Cancer Center, Greeley, Colorado, United States
🇺🇸The University of Alabama at Birmingham, Birmingham, Alabama, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.